The long-term outcome of patients with glycogen storage disease type Ia

G P Smit1

  • 1Department of Paediatrics, University Hospital of the University of Groningen, The Netherlands.

Insights

This study on pediatric patients found that frequent feeding regimens, including nocturnal gastric drip feeding, improved height standard deviation scores in 16 out of 20 patients. Liver adenomas and hypoglycemia were noted in some participants.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Gastroenterology

Background:

  • Glycogen storage disease type I (GSD Ia) is a rare inherited metabolic disorder.
  • Patients with GSD Ia often present with hypoglycemia, hepatomegaly, and growth failure.
  • Long-term complications include liver adenomas and metabolic derangements.

Purpose of the Study:

  • To retrospectively analyze clinical characteristics and outcomes in a cohort of GSD Ia patients.
  • To evaluate the efficacy of intensive feeding regimens on growth and metabolic parameters.
  • To assess the prevalence of complications such as liver adenomas and hyperlipidemia.

Main Methods:

  • Retrospective analysis of 41 patients (age >10 years) from five European centers.
  • Assessment of clinical data including height percentile, hypoglycemia, hepatomegaly, and biochemical markers.
  • Prospective evaluation of 20 patients before and after at least 5 years of intensive feeding therapy (daytime feeds + nocturnal gastric drip).

Main Results:

  • 19 patients were below the 3rd height percentile; 6 experienced hypoglycemia.
  • Hepatomegaly was present in 39/40 patients; 11/27 had marked hepatomegaly.
  • Liver adenomas detected in 11/39 patients; hypercholesterolemia and hypertriglyceridemia were common.
  • Intensive feeding improved height standard deviation scores (SDS) in 16/20 patients (responders).

Conclusions:

  • Intensive feeding regimens, including nocturnal gastric drip, significantly improve growth in GSD Ia patients.
  • Despite treatment, hypoglycemia and hepatomegaly persist in a subset of patients.
  • Regular monitoring for liver adenomas and metabolic complications remains crucial in GSD Ia management.

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.